共 50 条
- [21] HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer CellsPLOS ONE, 2008, 3 (08):Kong, AnthonyCalleja, VeroniqueLeboucher, PierreHarris, AdrianParker, Peter J.Larijani, Banafshe
- [22] Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2PLOS ONE, 2009, 4 (06):Kim, Hwang-PhillYoon, Young-KwangKim, Jin-WonHan, Sae-WonHur, Hyung-SeokPark, JinahLee, Ju-HeeOh, Do-YounIm, Seock-AhBang, Yung-JueKim, Tae-You
- [23] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitorsCANCER CELL, 2006, 10 (01) : 25 - 38Wang, Shizhen EmilyNarasanna, ArchanaPerez-Torres, MarianelaXiang, BinWu, Frederick Y.Yang, SeungchanCarpenter, GrahamGazdar, Adi F.Muthuswamy, Senthil K.Arteaga, Carlos L.
- [24] Targeting of EGFR and HER2 with therapeutic antibodies and siRNASTRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 (02) : 180 - 191Wichmann, HenriGuettler, AntjeBache, MatthiasTaubert, HelgeRot, SwetlanaKessler, JacquelineEckert, Alexander W.Kappler, MatthiasVordermark, Dirk
- [25] Differences underlying EGFR and HER2 oncogene addictionCELL CYCLE, 2010, 9 (05) : 851 - 852Faber, Anthony C.Wong, Kwok-KinEngelman, Jeffrey A.
- [26] Imaging EGFR and HER2 by PET and SPECT: A ReviewMEDICINAL RESEARCH REVIEWS, 2014, 34 (03) : 596 - 643Corcoran, Emily B.Hanson, Robert N.
- [27] EGFR AND HER2: PROTOTYPES OF FUTURE CANCER THERAPYANNALS OF ONCOLOGY, 2012, 23 : 11 - 11Yarden, Y.
- [28] SORLA regulates endosomal trafficking and oncogenic fitness of HER2Nature Communications, 10Mika PietiläPranshu SahgalEmilia PeuhuNiklas Z. JänttiIlkka PaateroElisa NärväHussein Al-AkhrassJohanna LiljaMaria GeorgiadouOlav M. AndersenArtur PadzikHarri SihtoHeikki JoensuuMatias BlomqvistIrena SaarinenPeter J. BoströmPekka TaimenJohanna Ivaska
- [29] Transactivation of HER2 by phosphorylated HER3 and EGFR correlates with clinicopathological end points in HER2 negative NSCLCJOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S897 - S898Mohan, KamleshDodson, AndrewGosney, JohnCarr, MartinThomas, AndrewWomack, ChrisJenkins, MartinMcGuire, JoeWalshaw, MartinArmour, Alison
- [30] SORLA regulates endosomal trafficking and oncogenic fitness of HER2NATURE COMMUNICATIONS, 2019, 10 (1)Pietila, MikaSahgal, PranshuPeuhu, EmiliaJantti, Niklas Z.Paatero, IlkkaNarva, ElisaAl-Akhrass, HusseinLilja, JohannaGeorgiadou, MariaAndersen, Olav M.Padzik, ArturSihto, HarriJoensuu, HeikkiBlomqvist, MatiasSaarinen, IrenaBostrom, Peter J.Taimen, PekkaIvaska, Johanna